StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

4-Butyl-1-(4-hydroxyphenyl)-2-phenyl-3,5-pyrazolidindion

Oxazolidin

HCID 4641
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
129-20-4
Standard-SMILES
CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O
InChIKey
HFHZKZSRXITVMK-UHFFFAOYSA-N
Summenformel
C19H20N2O3
Durchschnittliche Molmasse
324,4 g/mol
Monoisotopische Masse
324,1473925

Überblick

Oxyphenbutazone is a metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome. It has a role as an antimicrobial agent, a non-steroidal anti-inflammatory drug, a non-narcotic analgesic, an antipyretic, an antineoplastic agent, a gout suppressant, a drug metabolite and a xenobiotic metabolite. It is a member of phenols and a member of pyrazolidines. It is functionally related to a phenylbutazone.

Namen und Bezeichner

Bevorzugter Name
Oxazolidin
IUPAC
4-butyl-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione
Lokaler Name
4-Butyl-1-(4-hydroxyphenyl)-2-phenyl-3,5-pyrazolidindion
Englischer Name
OXYPHENYL BUTAZONE
Summenformel
C19H20N2O3
Molmasse
324.37

Namen und Synonyme

oxyphenbutazone129-20-4OxyphenylbutazoneTandearilFlogitoloFlogorilFrabelOxalidNeo-FarmadolCrovarilOxazolidinVisubutina
Weitere Namen anzeigen
bm1BM 1Flogalg27202IridilMysiteNeofen
OxifenylbutazonOxiphenbutazoneButapironeCalifornitTandacoteFlamarilOxyphenobutazonep-Oxyphenylbutazone

Datenbank-Bezeichner

CAS
129-20-4、7081-38-1
PubChem CID
4641
DTXSID
DTXSID1045291
ChEMBL
CHEMBL1228、CHEMBL3989676
ChEBI
CHEBI:76258
UNII
A7D84513GV
EC Number
204-936-2
Nikkaji
J10.648H

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
2,7
Polarare Oberfläche (TPSA)
60,9 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
3
Frei drehbare Bindungen
5
Schwere Atome
24
Formalladung
0
Komplexität
454

Experimentelle und physikochemische Eigenschaften

LogP3.04
OdorODORLESS
Color/FormWHITE TO YELLOWISH WHITE, CRYSTALLINE POWDER
Solubility · 2 Einträge

ANHYDROUS CRYSTALS FROM ETHER & PETROLEUM ETHER WITH MP 124-125 °C; ACIDIC REACTION; MP 96 °C; FORMS WATER-SOL SODIUM SALT; SOL IN ETHANOL, METHANOL, CHLOROFORM, BENZENE, ETHER /MONOHYDRATE/

VERY SLIGHTLY SOL IN WATER; FREELY SOL IN ACETONE

Human Drugs · 3 Einträge

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Collision Cross Section · 3 Einträge

163.33 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

177.2 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

184.74 Ų [M-H]-

Physikochemische Eigenschaften

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P273, P301+P317, P330, P391, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 40 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Other Safety InformationIMAP assessments - 3,5-Pyrazolidinedione, 4-butyl-1-(4-hydroxyphenyl)-2-phenyl-: Human health tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (100%)

Toxikologische Informationen

Interactions · 5 Einträge

SOME TRICYCLIC COMPD HAVE BEEN SHOWN TO DELAY OXYPHENYLBUTAZONE ABSORPTION IN RAT BY INCR GASTRIC EMPTYING TIME.

...OXYPHENBUTAZONE MAY PROLONG PROTHROMBIN TIME IN PT RECEIVING COUMARIN ANTICOAGULANTS CONCOMITANTLY & MAY INCR HYPOGLYCEMIC EFFECT OF INSULIN & ORAL HYPOGLYCEMIC AGENTS.

WHEN OXYPHENBUTAZONE & METHANDROSTENOLONE ARE ADMIN CONCURRENTLY IN HUMANS, SERUM OXYPHENBUTAZONE LEVELS MAY BE ELEVATED. PT TREATED WITH THESE CONCURRENTLY SHOULD BE MONITORED FOR SIGNS OF OXYPHENBUTAZONE-INDUCED ADVERSE EFFECTS.

OXYPHENBUTAZONE ABSORPTION...IS DECR BY DESIPRAMINE.

For more Interactions (Complete) data for OXYPHENBUTAZONE (6 total), please visit the HSDB record page.

Human Toxicity Excerpts · 5 Einträge

NAUSEA, VOMITING, EPIGASTRIC DISCOMFORT, & SKIN RASHES ARE MOST FREQUENTLY REPORTED UNTOWARD EFFECTS. DIARRHEA, VERTIGO, INSOMNIA, EUPHORIA, NERVOUSNESS, HEMATURIA...& BLURRED VISION HAVE ALSO BEEN OBSERVED. ...WATER & ELECTROLYTE RETENTION & EDEMA FORMATION OCCUR. /PHENYLBUTAZONE/

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 6 Einträge

S - Sensory organs

M - Musculo-skeletal system

M - Musculo-skeletal system

QM - Musculo-skeletal system

QS - Sensory organs

QM - Musculo-skeletal system

Mechanism of Action · 1 Eintrag

...HAS PROMINENT ANTI-INFLAMMATORY EFFECTS IN ANIMALS, & COMPARABLE EFFECTS... IN PT WITH RHEUMATOID ARTHRITIS & RELATED DISORDERS. ...INHIBITS BIOSYNTHESIS OF PROSTAGLANDINS, UNCOUPLES OXIDATIVE PHOSPHORYLATION, & INHIBITS ATP-DEPENDENT BIOSYNTHESIS OF MUCOPOLYSACCHARIDE SULFATES IN CARTILAGE. /PHENYLBUTAZONE/

Biological Half-LifeIN MAN, OXYPHENBUTAZONE HAS BIOLOGICAL HALF-LIFE OF ABOUT 2 DAYS.
Metabolism/MetabolitesOXIDN OF PHENYLBUTAZONE DURING CHRONIC DOSING BY MEASURING URINARY EXCRETION OF 3 METABOLITES, OXYPHENBUTAZONE GAMMA-HYDROXYPHENBUTAZONE & P,GAMMA-HYDROXYPHENBUTAZONE DURING INFUSION OF HYDROCORTISONE SODIUM SUCCINATE IS REPORTED.
MeSH Pharmacological Classification · 1 Eintrag

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

Absorption, Distribution and Excretion · 1 Eintrag

...OXYPHENBUTAZONE IS EXTENSIVELY BOUND TO PLASMA PROTEINS & HAS PLASMA HALF-TIME OF SEVERAL DAYS. ...ONLY SLOWLY EXCRETED IN URINE, SINCE BINDING TO PLASMA PROTEIN LIMITS...GLOMERULAR FILTRATION, &...RELATIVELY HIGH PKA, WHICH FAVORS PASSIVE REABSORPTION IN DISTAL TUBULE.

Verwendung und Herstellung

Zugehörige Reaktionen

5
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 259177
HRID 259177als Edukt
Reaktionsgleichung von HRID 1076799
HRID 1076799als Edukt
Reaktionsgleichung von HRID 1390723
HRID 1390723als Edukt
Reaktionsgleichung von HRID 1764768
HRID 1764768als Edukt
Reaktionsgleichung von HRID 1863518
HRID 1863518als Edukt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
Schmelzpunkt
109 · 109-111°C
Siedepunkt
462.71 °C · 462.71°C (rough estimate)
Dichte
1.2118 · 1.2118 (rough estimate)
Brechungsindex
1.614 · 1.6140 (estimate)
storage temp.
-20 °C · -20°C
Löslichkeit
10 mg/mL, · DMSO: soluble10mg/mL, clear
pka
4.7 · pKa 4.7/10.0±0.2(H2O,t =25,Iundefined) (Uncertain)
Aggregatzustand
powder
Farbe
white to brown
Wasserlöslichkeit
20 mg/L · 20mg/L(room temperature)
Stabilität
Hygroscopic
InChI
1S/C19H20N2O3/c1-2-3-9-17-18(23)20(14-7-5-4-6-8-14)21(19(17)24)15-10-12-16(22)13-11-15/h4-8,10-13,17,22H,2-3,9H2,1H3
InChIKey
HFHZKZSRXITVMK-UHFFFAOYSA-N
SMILES
N2(N(C(=O)C(C2=O)CCCC)c3ccccc3)c1ccc(cc1)O
CAS Datenbank
129 · 129-20-4(CAS DataBase Reference)
EPA chemische Informationen
3 · 3,5-Pyrazolidinedione, 4-butyl-1-(4-hydroxyphenyl)-2-phenyl- (129-20-4)

MORE SERIOUS FORMS OF ADVERSE EFFECTS INCL PEPTIC ULCER...WITH HEMORRHAGE OR PERFORATION, HYPERSENSITIVITY REACTIONS OF SERUM-SICKNESS TYPE, ULCERATIVE STOMATITIS, HEPATITIS, NEPHRITIS, APLASTIC ANEMIA, LEUKOPENIA, AGRANULOCYTOSIS, & THROMBOCYTOPENIA. NUMBER OF DEATHS HAVE OCCURRED... /PHENYLBUTAZONE/

...32-YR OLD WOMAN WHO WAS TREATED WITH 2.5 G OXYPHENBUTAZONE OVER 7 DAYS; SHE...DEVELOPED SEVERE LEUCOCYTOSIS FOLLOWED BY LEUCOPENIA & ANEMIA...SUBSEQUENT RECOVERY.

ADMIN OF PHENYLBUTAZONE...IS ASSOC WITH...BONE MARROW SUPPRESSION. TOXICITY OF OXYPHENBUTAZONE IS SIMILAR TO THAT OF PARENT COMPD... /PHENYLBUTAZONE/

NUMBER OF CASES OF LEUKEMIA WERE REPORTED BETWEEN 1960 & 1966 IN SUBJECTS TREATED WITH PHENYLBUTAZONE OR OXYPHENBUTAZONE. AVAIL EVIDENCE IS, HOWEVER, INSUFFICIENT TO SUBSTANTIATE SUGGESTION THAT USE...IS RELATED TO SUBSEQUENT DEVELOPMENT OF LEUKEMIA.

Carcinogen Classification · 5 Einträge

Oxyphenbutazone

Group 3: Not classifiable as to its carcinogenicity to humans

Volume 13: (1977) Some Miscellaneous Pharmaceutical Substances

1987

1987

Drug Induced Liver Injury · 4 Einträge

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Oxyphenbutazone

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

Non-Human Toxicity Excerpts · 2 Einträge

.../PHENYLBUTAZONE/ DID NOT INDUCE NON-DISJUNCTION OR CROSSING-OVER IN ASPERGILLUS NIDULANS IN ABSENCE OF METABOLIC ACTIVATION, WHEREAS ITS METABOLITE, OXYPHENBUTAZONE, HAD WEAK BUT SIGNIFICANT ACTIVITY.

GASTRIC ULCERATIONS WERE PRODUCED IN DOGS AFTER PROLONGED IM ADMIN OF DOSES OF 3.6-35.2 G PHENYLBUTAZONE OVER 10-103 DAYS. /PHENYLBUTAZONE/

Evidence for CarcinogenicityNo data are available in humans. No data are available in animals. OVERALL EVALUATION: Group 3: The agent is not classifiable as to its carcinogenicity to humans.

Sicherheitsdaten

wgk
3
ridadr
UN 3077 9 / PGIII
risk_code
22-50
hazard_code
Xn,N
safety_code
61
Speicherklasse
11 - Combustible Solids
Giftige Stoffe Daten
129-20-4(Hazardous Substances Data)
Hazard Classifications
Acute Tox. 4 OralAquatic Acute 1
Uses · 2 Einträge

MEDICATION

MEDICATION (VET)

Methods of ManufacturingHAFLIGER, US PATENT 2,745,783 (1956 TO GEIGY): PFISTER, HAFLIGER, HELV CHIM ACTA 40, 395 (1957).
Formulations/PreparationsOXYPHENBUTAZONE, NF (TANDEARIL), IS MARKETED IN 100-MG TABLETS.
Use ClassificationPharmaceuticals
General Manufacturing Information · 1 Eintrag

OXYPHENBUTAZONE IS HYDROXY ANALOG OF PHENYLBUTAZONE & ONE OF MAJOR ACTIVE METABOLITES OF PARENT DRUG. ... OXYPHENBUTAZONE HAS SAME SPECTRUM OF ACTIVITY, THERAPEUTIC USES, INTERACTIONS, & TOXICITY AS PARENT COMPD, & IT SHARES SAME INDICATIONS, DANGERS, & CONTRAINDICATIONS FOR CLINICAL USE.

Anwendungen

VerwendenAnti-inflammatory;Cyclooxygenase inhibito

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

1-phenyl-2-[4-(phenylmethoxy)phenyl]hydrazineWasserstoffNatrium
Ergänzende Hinweise · 1 Eintrag

DefinitionChEBI: A metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following asso iation with blood dyscrasis and Stevens-Johnson syndrome.